Real-time imaging of histone H4 hyperacetylation in living cells

Kazuki Sasaki, Tamaki Ito, Norikazu Nishino, Saadi Khochbin, and Minoru Yoshida

Edited by Tom Misteli, National Cancer Institute, Bethesda, MD, and accepted by the Editorial Board July 30, 2009 (received for review March 2, 2009)

To visualize histone acetylation in living cells, we developed a genetically encoded fluorescent resonance energy transfer (FRET)-based indicator. Response of the indicator reflects changes in the acetylation state of both K5 and K8 in histone H4. Using this acetylation indicator, we were able to monitor the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors.

Covalent modification of core histones plays an important role in the modulation of chromatin structure and function. Acetylation is a well-characterized modification regulated by two families of evolutionarily conserved enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs) (1, 2). Acetylation mainly occurs on lysine residues of core histone N-terminal tails; in this context, the modification induces chromatin conformational change by unfolding higher order chromatin structure, and represents an epigenetic mark recognized by regulatory factors including coactivators. Core histone acetylation influences gene expression by modifying chromatin conformation and/or the recruitment of the regulatory factors. The acetylation of histone H4 is thought to occur initially at K16, and then propagates through K12, K8, and K5, progressing in an N-terminal direction (3). Thus, the simultaneous acetylation of both K5 and K8 in histone H4 is indicative of histone H4 hyperacetylation (4, 5). Acetylated histones are recognized by regulatory proteins containing bromodomodomains, for example, PCAF, Brd2, Brd4, and BRDT (6). Recently, it has been suggested that each distinct combination of covalent modifications of histone tails functions as an epigenetic code by regulating the interaction of histone tails with chromatin-associated proteins (7).

In vivo histone acetylation is reversibly and dynamically regulated. However, in most studies on protein acetylation, conventional biochemical methods such as immunostaining have been used. These methods do not always provide enough information about the temporal and spatial dynamics of protein acetylation in living cells. In the case of other cellular dynamics, such as intracellular Ca$^{2+}$ and protein phosphorylation, visualization by fluorescence resonance energy transfer (FRET) in live cells has been used to successfully overcome the limitations of conventional methods (8). Here, we report a FRET-based indicator, named Histac, developed to allow visualization of protein acetylation in living cells.

Results

A Fluorescent Indicator for Histone H4 Hyperacetylation. For use as an indicator, we developed a five-part tandem fusion protein consisting of an acetylation-binding domain, a flexible linker, a substrate histone H4, and the two different-colored mutants of GFP (CFP and Venus), which serve as the donor and acceptor fluorophores, respectively, for FRET (Fig. 1A).

Acetylation of the substrate histone H4 and subsequent binding of the acetylated substrate histone H4 to the acetylation-binding domain induce a conformational change in the indicator protein. The acetylation-dependent conformational change in the indicator alters the distance and orientation between CFP and Venus, thus generating a change in intramolecular FRET. The bromodomain region of BRDT, which contains two bromodomains, was used as the acetylation-binding domain (9). The peptide pull-down analysis revealed that this bromodomain region specifically bound to histone H4 peptides in which both K5 and K8 were acetylated (Fig. 1B).

Author contributions: K.S. designed research; K.S. and T.I. performed research; N.N. and S.K. contributed new reagents/analytic tools; K.S. analyzed data; and K.S., S.K., and M.Y. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. T.M. is a guest editor invited by the Editorial Board.

1To whom correspondence should be addressed. E-mail: yoshidam@riken.jp.

This article contains supporting information online at www.pnas.org/cgi/content/full/0902150106/DCSupplemental.
Histac colocalized with nuclear DNA stained by Hoechst 33342 in COS7 cell (Fig. S2A). The ratios of fluorescence intensities between DNA and Venus determined at a number of distinct chromatin regions were essentially the same, suggesting that Histac is uniformly incorporated into chromatin (Fig. S2B). On the other hand, a mutant lacking the C-terminal globular domain of histone H4 (Histac-ΔC-H4) was located in both the nucleoplasm and the cytoplasm (Fig. S3A). To further investigate whether Histac was incorporated into nucleosomes, we fractionated extracts of the cells expressing Histac. Immunoblot analysis of cytoplasmic (Cy), nucleoplasmic (Nu), and chromatin (Ch) fractions showed that Histac was localized in the chromatin fraction, whereas Histac-ΔC-H4 was present in both the cytoplasmic and the nucleoplasmic fractions, indicating that the histone H4 globular domain is responsible for its chromatin association (Fig. S2C). In addition, we examined the effect of Histac expression on chromatin structure by determining the length of nucleosome repeat length. No difference between COS7 cells expressing Histac and the untransfected cells or those expressing histone H4 domain (Histac-ΔC-H4) was detected in the micrococcal nuclease digestion patterns (Fig. S2D).

The acetylation of Histac, as determined using immunoblotting (Fig. 2A and C). After the removal of TSA from the culture, both emission ratio and acetylation of Histac rapidly returned to the basal levels, indicating that Histac is a reversible indicator for monitoring acetylation of histone H4 in living cells (Fig. S4 and Movie S2). The cellular response in HeLa cells was essentially the same as in COS7 cells (Fig. S5). Photobleaching of Venus resulted in an increase in CFP fluorescence (Fig. S6), and the photobleached indicator no longer responded to TSA (Fig. 2D). These results confirm that the change in emission ratio reflects the change in FRET from CFP to Venus.

Mutational Analysis of the Acetylation-Binding Domain. To confirm that the TSA-induced change in FRET is a result of the binding of acetylated histone H4 domain to the acetylation-binding domain, we examined the effects of mutations in the Histac acetylation-binding domain (Fig. 4A). When two tyrosine residues were replaced with alanine in the acetylation-binding domain (2YA), the double-bromodomain mutant became incapable of binding to acetylated histone H4 (Fig. 4B) and failed to respond to TSA (Fig. 4C). The single Y65A mutant in bromodomain 1 was also impaired in its ability to bind to acetylated histone H4 (Fig. 4B) and did not show any detectable change in the emission ratio upon TSA treatment (Fig. 4C). In contrast, the Y308A mutant in bromodomain 2 retained the ability to bind to acetylated histone H4 (Fig. 4B) and showed a marked emission ratio change in response to TSA (Fig. 4C). No significant difference in the FRET response was observed between Histac and Histac-Y308A, suggesting that the major domain for recognizing acetylated histone H4 in BRDT is bromodomain 1.

Mutational Analysis of Acetylation Sites. To verify that the TSA-induced change in FRET reflects acetylation at the specific sites
of the histone H4 domain, we reciprocally tested the effects of mutations of acetylation sites in the histone H4 domain. Substitution of arginine for four lysines at the acetylation sites K5, K8, K12, and K16 of histone H4 in the indicator (Histac-4KR) caused a significant decrease in the response to TSA (Fig. 5A). We further examined the effects of each acetylation site mutation on the emission ratio (Fig. 5A). Consistent with the peptide binding analysis (Fig. 1B), replacement of both K5 and K8 with arginine resulted in a marked decrease in the response to TSA treatment compared with Histac. Single substitutions at either K5 or K8 showed a decrease in the response to TSA treatment, but the decrease was smaller than that observed with the double substitution mutant K5,R8. The emission ratio change was not affected by K12R, indicating that acetylation of K12 does not contribute to the binding of BRDT. Surprisingly, the response intensity of K12,R8 was almost the same as that of K5,R8. Since acetylated K12 is not the binding site for the bromodomains of BRDT, this result suggests that K12 acetylation affects the K5 acetylation. Indeed, Western blot analysis revealed that the K12,R8 mutant was barely acetylated at K5, but fully acetylated at K8 (Fig. 5B). On the other hand, K5,R8 and K16R did not affect the acetylation of other sites. We further confirmed these results using histone H4 mutants bearing much smaller tags, to rule out any effects of the fluorescent proteins fused to histone H4 (Fig. 5C). Again, acetylation of K5 seemed to be largely dependent on acetylation of K12.

**Live Imaging of Histac During Mitosis.** There is no significant difference in the acetylation level of K5 in histone H4 between metaphase and interphase (11). On the other hand, HDAC inhibitors cause G2/M cell cycle arrest and mitotic checkpoint activation (12, 13), suggesting that histone deacetylation is involved in the progression of mitosis. Recent analyses using immunofluorescence staining, immunoblotting and mass spectrometry suggest that deacetylation at histone H4 K5 occurs in mitosis (14–16). However, because of technical limitations on the biochemical methods used in these studies, the dynamic fluctuation of the K5 acetylation state in histone H4 during mitosis remains controversial. We therefore used Histac to determine whether histone H4 acetylation can be dynamically regulated during mitosis. As shown in Fig. 6A and B, the level of histone H4 acetylation started to decrease at the onset of prophase, was minimized at anaphase, and recovered after progression into G1 (Movie S3). Chromatin condensation during mitosis might cause a FRET response unrelated to acetylation. However, the decrease in the FRET emission ratio of Histac-4KR was not observed during mitosis (Fig. 6B and Fig. S7). Furthermore, live cell chromatin compaction assay was performed to see whether condensed chromatin structure affects the FRET response (17). Time-lapse images were recorded during 30 min after an osmolarity shift-up in the medium from 290 (physiological condition) to 570 mOsm (Fig. S8). The intensity of Venus was increased due to the chromatin compaction, but no significant change in the emission ratio was observed in the same regions in the nuclei. These data indicate that the chromatin condensation itself has no apparent effect on the FRET response. The decrease in the level of histone H4 acetylation during mitosis was validated by immunoblotting (Fig. 6C). Consistent with microscopic observations, the amount of acetylated histone H4 K5 was much lower in the nocodazole-arrested COS7 cells than in asynchronous cells.

**Live Imaging of Histac During Interphase.** To examine whether different FRET response occurs between nuclear subdomains, we analyzed the response to TSA in the interphase cells expressing Histac by confocal fluorescence microscopy (Fig. S9). The FRET responses in two distinct chromatin regions surrounded by blue and yellow lines were compared (Fig. S9A). No significant difference between the two regions in a nucleus expressing Histac was observed upon 1 μM TSA treatment in this particular experiment, suggesting that similar HAT activities are associated in these regions. In contrast, after removal of TSA from culture a difference in the kinetics of histone deacetylation was detected.
cell, a real-time imaging probe for in vivo histone acetylation has been long awaited. In this study, we showed that a FRET probe fused tandemly with the BRDT bromodomain and histone H4 enabled us to visualize the dynamic changes in histone H4 acetylation in living cells. Indeed, we could demonstrate the decrease in the level of histone H4 K5/K8 acetylation at metaphase. Although early observation suggested no significant change in acetylation of histone H4 K5, recent analyses using immunofluorescence staining, immunoblotting, and mass spectrometry demonstrated the opposite (14–16). The present study verified the dramatic decrease in K5 acetylation in mitosis. In immunofluorescence staining it cannot be ruled out that an antibody might be inaccessible to acetylated histones during mitosis, due to chromatin condensation. Moreover, because cell synchronization is required for immunoblotting and mass spectrometry, stress induced by the agents for cell synchronization might affect the histone acetylation state. Histac can bypass these technical challenges.

It is unclear why Histac-4KR still responded, albeit weakly, to TSA-induced hyperacetylation of histone H4 (Fig. 5A). It seems possible that Histac may form a nucleosome together with an endogenous histone H4 molecule, and that the bromodomain in Histac-4KR can interact with acetylated lysine residues in the flexible tail of the endogenous histone H4 in the same nucleosome. The X-ray structure analysis of a nucleosome showed that histone H4 possesses an unstructured N-terminal tail, leaving the flexible tail of the endogenous histone H4 in the same nucleosome. The X-ray structure of the nucleosome (PDB ID: 1EQZ) indicates that the distance between the residues of the two structured H4 N-terminal ends in a nucleosome is approximately 7.6 nm. The bromodomain in Histac is fused to the flexible N-terminal ends via a flexible 20-residue linker extension from the structured end. Therefore, it seems likely that the flexible intervening polypeptide bridges the gap to allow access of the bromodomains to the acetylation sites of the endogenous H4.

**Evaluation of HDAC Inhibitors in Living Cells.** Histac is a highly sensitive imaging probe for monitoring the activity of HDAC inhibitors in living cells. FK228, which is currently studied clinically (18), is another potent HDAC inhibitor. FK228 has an intramolecular disulfide bond, and is activated in cells by reduction to form two sulphydryl groups, one of which can interact with the HDAC active site (19). It was unclear, however, how much time is required for this process. Using Histac, we detected FK228 activity immediately after the challenge (Fig. 7A), indicating that FK228 is rapidly incorporated and activated in the cells. CHAP31 (20) and SCOP402 (21), cyclic tetrapeptides having a hydroxamic acid and a disulfide as functional groups, respectively, also showed rapid FRET responses (Fig. 7B and C). In contrast, SCOP304 (21), a dimer form of SCOP152 with a disulfide, gave significantly different kinetics (Fig. 7D). It showed a delayed response onset, and took more time than other HDAC inhibitors to reach a plateau, probably due to poor membrane permeability. Based on these inhibitor data, it is clear that Histac serves as a powerful assay tool for in vivo HDAC inhibitor action.

**Discussion**

Before the existence of Histac, Kanno et al. (22) developed a method to screen for bromodomains that interact with acetylated histone, using a flow cytometric adaptation of FRET termed FC-FRET. This approach enabled one to measure the steady-state interaction between bromodomain proteins and acetylated histones in living cells. However, because the state of histone acetylation is thought to be dynamically regulated in the cell, a real-time imaging probe for in vivo histone acetylation has...
In vitro pull-down experiments show a strict requirement for the acetylation at both K5 and K8 for the BRDT binding (Fig. 1B). This requirement appears less strict in vivo, because of the possible cross-talks between the bromodomain and acetylated K5 and K8 in the endogenous H4 in the same nucleosomes (Fig. S4). The simultaneous presence of acetylation on both K5 and K8 is a signature of H4 hyperacetylation. A zip model supports the idea that acetylation propagates from K16 to K5 and simultaneous acetylation at K5 and K8 should therefore indicate hyperacetylated H4 (3–5). Thus, Histac is a unique probe for imaging hyperacetylated histone H4. In this study, we demonstrate that the K12 acetylation is required for the efficient K5 acetylation, which may be one of the mechanisms underlying the acetylation at both K5 and K8 for the BRDT binding (Fig. 1B). Histac to recognize the in vivo histone H4 acetylation correlated well with the properties of the interaction of BRDT with histone H4 in vitro. BRDT contains two bromodomains. The bromodomain structure consists of an atypical left-handed four-helix bundle (helices αZ, αX, αB, and αC), a long intervening loop between helices αZ and αX (termed the ZA loop), and a loop between helices αB and αC (termed the BC loop) (6). The ZA and BC loops form a hydrophobic pocket, to which an acetyl-lysine residue binds. Y65 (bromodomain 1) and Y308 (bromodomain 2) in the ZA loops in the BRDT bromodomains are highly conserved throughout the large family of bromodomains, including GCN5, TAFII250, CBP, p300, and Brd2. We found that the substitution of alanine for Y65 in bromodomain 1 is sufficient to impair its ability to bind to acetylated histone H4. On the other hand, Y308A did not abolish the binding of BRDT to acetylated histone H4. These results suggest that bromodomain 1 in BRDT is the primary binding domain for acetylated histone H4, and bromodomain 2 is the secondary domain. This idea is consistent with the observation that BRDT containing a mutation in the bromodomain 1 (P50A, F51A, and V55A) could not induce chromatin remodeling, while BRDT containing a mutation in bromodomain 2 (P293A, F294A, and V298A) retained TSA-dependent chromatin remodeling activity (9).

In conclusion, we have developed an indicator for visualizing histone H4 acetylation in living cells. Since our indicator recognizes the acetylation of K5 and K8, the response reflects the hyperacetylation of histone H4 (3–5). It seems probable that exchange of the acetylation-binding domain with other bromodomains (e.g., Brd2 binds to acetylated K12 in histone H4 (22)) will allow monitoring of other acetylation sites. Our approach provides a tool for spatial and temporal analysis of protein acetylation, and will help to understand when, where, and how histone H4 is acetylated in living cells, tissues, and transgenic animals.

Materials and Methods

Plasmid Construction, Cell Culture, and Transfection. The cDNA of ECFP, Venus, histone H4, bromodomains of BRDT (BRDT-H4), and the linker were generated using PCR and cloned into the restriction sites shown in Fig. 1A. Each cDNA was subcloned into the KpnI-XhoI site of a mammalian expression vector, pcDNA3.1(+)(Invitrogen).

COS7 cells and HeLa cells were cultured in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids at 37 °C in 5% CO2. These cells were transfected with a FuGENE 6 transfection reagent (Roche) and then cultured for 24 h at 37 °C in 5% CO2.

Imaging of Cells. After transfection, the culture medium was replaced with phenol red-free growth medium for imaging. Cells were observed at 37 °C in 5% CO2 on an Olympus IX81 microscope with a U-IC-EQ cooled charged-coupled device camera (Molecular Devices). Images were collected by using a MetasFluor (Universal Imaging) with a 440AF21 excitation filter, a 455DRLP dichroic mirror, and two emission filters (480AF30 for CFP and 535AF26 for Venus). For Fig. S2, the images of Hoechst 33342 staining and Venus were collected with FV1000 (Olympus) confocal microscope system.

Gel Electrophoresis and Immunoblot Analysis. For Figs. 18 and 46, peptide pull-down assays were performed as described by Pivot-Pajot et al. (9). COS7 cells were transiently transfected with monomeric Venus-BRDT or monomeric Venus-BRDT-mutants. For Fig. S2C, mononucleosome core particles were purified as described by Kanada et al. (25). The fractions were immunoprecipitated using an anti-GFP antibody (Takara Bio).

Immunoblot analysis was performed using standard procedures and visualized using ECL Western Blotting Detection Reagents (GE Healthcare Bio-Science Corp.). The antibodies that recognize acetyl-lysine 5, 8, 12, and 16, respectively, of histone H4 were obtained from Upstate Biotechnology. The anti-histone H3, anti-histone H4, anti-GFP, and anti-FLAG antibodies were purchased from Cell Signaling Technology, Abcam, Takara Bio, and Sigma, respectively. The anti-HDAC1 and anti-tubulin were obtained from Sigma.

Micrococcal Nuclease Digestion. Micrococcal nuclease digestion was carried out essentially as described by Remboutsika et al. (26). The nucleus of COS7 cells expressing the indicators were digested with increasing amounts of micrococcal nuclease (0.2, 0.8, or 3.2 units per 107 nucleus) (Sigma) at 37 °C for 10 min. DNA was purified by phenol/chloroform extraction and ethanol precipitation, and separated in a 2% agarose gel.

ACKNOWLEDGMENTS. We thank Atsushi Miyawaki (RIKEN, Japan) for providing various Venus mutants and helpful discussion, A. Gansevan (University of Southampton and Karus Therapeutics Ltd., U.K.) for providing FK228, and Akihiro Ito for discussion; BSI’s Research Resources Center for providing DNA sequencing analysis and peptide synthesis; and RIKEN BSI-Olympus Collaborative Center for imaging equipment and software. This work was supported in part by Grant-in-aid for Scientific Research on Priority Areas (to K.S.); CREST Research Project, JST, Grants-in-aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to M.Y.), and “ANR blanc” “Epimape, INCA,” and “ARC-ARECA” research programs (to S.K.).